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Abstract
Objectives
To characterize the clinical severity of covid-19
associated with the alpha, delta, and omicron SARSCoV-2 variants among adults admitted to hospital
and to compare the effectiveness of mRNA vaccines
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variant.
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Design
Case-control study.
Setting
21 hospitals across the United States.
Participants
11 690 adults (≥18 years) admitted to hospital: 5728
with covid-19 (cases) and 5962 without covid-19
(controls). Patients were classified into SARS‑CoV‑2

What is already known on this topic
Two doses of mRNA vaccines were highly effective for preventing hospital
admissions with covid-19 due to the alpha and delta variants during the first year
of the covid-19 vaccination programme in the United States
Authorized third doses of mRNA covid-19 vaccines were administered from
August 2021 in an effort to maintain vaccine effectiveness over time

What this study adds
Effectiveness of two doses of an mRNA vaccine to prevent hospital admission
with covid-19 was found to be lower for the omicron variant than alpha and delta
variants (65%, 85%, and 85%, respectively), whereas three vaccine doses were
found to achieve effectiveness against the omicron variant (86%) similar to two
doses against the alpha and delta variants
The severity of disease among patients admitted to hospital with covid-19 was
found to be lower with the omicron versus delta variant
Patients with the omicron variant were, however, found to be at risk of critical
illness and death, with 15% of patients with the omicron variant in this study
progressing to invasive mechanical ventilation and 7% to death
the bmj | BMJ 2022;376:e069761 | doi: 10.1136/bmj-2021-069761

variant groups based on viral whole genome
sequencing, and, if sequencing did not reveal a
lineage, by the predominant circulating variant at
the time of hospital admission: alpha (11 March to 3
July 2021), delta (4 July to 25 December 2021), and
omicron (26 December 2021 to 14 January 2022).
Main outcome measures
Vaccine effectiveness calculated using a test negative
design for mRNA vaccines to prevent covid-19 related
hospital admissions by each variant (alpha, delta,
omicron). Among patients admitted to hospital
with covid-19, disease severity on the World Health
Organization’s clinical progression scale was
compared among variants using proportional odds
regression.
Results
Effectiveness of the mRNA vaccines to prevent
covid-19 associated hospital admissions was 85%
(95% confidence interval 82% to 88%) for two vaccine
doses against the alpha variant, 85% (83% to 87%)
for two doses against the delta variant, 94% (92% to
95%) for three doses against the delta variant, 65%
(51% to 75%) for two doses against the omicron
variant; and 86% (77% to 91%) for three doses
against the omicron variant. In-hospital mortality
was 7.6% (81/1060) for alpha, 12.2% (461/3788)
for delta, and 7.1% (40/565) for omicron. Among
unvaccinated patients with covid-19 admitted to
hospital, severity on the WHO clinical progression
scale was higher for the delta versus alpha variant
(adjusted proportional odds ratio 1.28, 95%
confidence interval 1.11 to 1.46), and lower for the
omicron versus delta variant (0.61, 0.49 to 0.77).
Compared with unvaccinated patients, severity
was lower for vaccinated patients for each variant,
including alpha (adjusted proportional odds ratio
0.33, 0.23 to 0.49), delta (0.44, 0.37 to 0.51), and
omicron (0.61, 0.44 to 0.85).
1
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Conclusions
mRNA vaccines were found to be highly effective in
preventing covid-19 associated hospital admissions
related to the alpha, delta, and omicron variants,
but three vaccine doses were required to achieve
protection against omicron similar to the protection
that two doses provided against the delta and alpha
variants. Among adults admitted to hospital with
covid-19, the omicron variant was associated with less
severe disease than the delta variant but still resulted
in substantial morbidity and mortality. Vaccinated
patients admitted to hospital with covid-19 had
significantly lower disease severity than unvaccinated
patients for all the variants.

Introduction
The covid-19 pandemic has been defined by both
the distribution of highly effective vaccines and
the serial emergence of new SARS-CoV-2 genetic
variants.1 Variants of concern are new genetic
versions of the virus with increased transmissibility,
a change in virulence or disease presentation, or a
decrease in effectiveness of mitigation measures,
available vaccines, or treatments.2 Five World Health
Organization designated SARS-CoV-2 variants of
concern are currently recognized: alpha (B.1.1.7
and descendant lineages), beta (B.1.351), gamma
(P.1), delta (B.1.617.2 and AY lineages), and omicron
(B.1.1.529 and BA lineages).
The highly contagious delta variant was first
identified in spring 2021 and rapidly replaced other
SARS-CoV-2 variants, achieving global dominance by
summer 2021.3 Early studies suggested the potential
for increased risk of hospital admissions for people
infected with the delta variant compared with previous
variants.4-6 The highly divergent omicron variant was
identified in mid-November 2021 and quickly became
the dominant variant in much of Europe and North
America by late December 2021.7 The overall risk of
hospital admission among those infected with the
omicron variant seems to be lower than among those
infected with the delta variant.8 Hospital admissions for
infection due to the omicron variant do, however, occur,
and disease severity and risk for progression to critical
illness remain incompletely understood for this variant.
Understanding the epidemiology of SARS-CoV-2
variants and the effectiveness of existing vaccines
against them are essential to guide vaccination
policies and the development of new vaccines. Early
studies suggested reduced vaccine effectiveness
against infection and hospital admissions for omicron
compared with earlier variants.9-11 In most prior
studies, estimates of vaccine effectiveness against the
omicron variant were based on infections that occurred
during periods in which the omicron variant exceeded
50% in genomic surveillance. Although efficient, these
approaches have the potential for misclassification
of the variant and inaccurate estimates of vaccine
effectiveness. Furthermore, little is known about the
effectiveness of vaccines to prevent the most severe
manifestations of covid-19, including respiratory
2

failure and death, for patients with infection due to the
omicron variant.
Using observational study designs, the Influenza
and Other Viruses in the Acutely Ill (IVY) Network in
collaboration with the US Centers for Disease Control
and Prevention is studying the effectiveness of covid-19
vaccines against severe disease (see supplementary
table S1).12-15 Here, we compare the clinical severity
of covid-19 associated with the SARS-CoV-2 alpha,
delta, and omicron variants among adults admitted to
hospital in the United States, and the effectiveness of
covid-19 mRNA vaccines against each of these variants.

Methods
Design and setting
We conducted a prospective observational study at 21
hospitals in the US, with enrollment of adults admitted
to hospital with laboratory confirmed covid-19 (cases)
and concurrent patients without covid-19 (controls).
A test negative design was utilized to assess vaccine
effectiveness.16 This programme was conducted
by the IVY Network, which is a group consisting of
geographically dispersed academic medical centers
in the US, coordinated from Vanderbilt University
Medical Center (Nashville, TN) and funded by CDC
(see supplementary table S1). Participants enrolled
in the IVY programme with hospital admission dates
between 11 March 2021 and 14 January 2022 were
included in this analysis.
In this analysis we compared the alpha, delta, and
omicron SARS-CoV-2 variants in three ways: vaccine
effectiveness of mRNA vaccines to prevent hospital
admissions with each variant; disease severity among
unvaccinated and vaccinated patients with each
variant admitted to hospital; and vaccine effectiveness
of mRNA vaccines to prevent disease progression to
invasive mechanical ventilation or death after hospital
admission with each variant.
Participants
Sites prospectively screened in-hospital adults aged
18 years or older for potential eligibility through
daily review of hospital admission logs and electronic
medical records. Cases with covid-19 included
those admitted to hospital with a clinical syndrome
consistent with acute covid-19 (≥1 of fever, cough,
shortness of breath, loss of taste, loss of smell, use
of respiratory support for the acute illness, or new
pulmonary findings on chest imaging consistent with
pneumonia) and a positive molecular or antigen test
result for SARS-CoV-2 within 10 days of symptom
onset. We subclassified case patients based on SARSCoV-2 variant. Additionally, two control groups were
enrolled: test negative controls, who were adults
admitted to hospital with signs or symptoms consistent
with acute covid-19 and tested negative for SARSCoV-2; and syndrome negative controls, who were
adults admitted to hospital without signs or symptoms
consistent with acute covid-19 and tested negative
for SARS-CoV-2.17 Controls were selected from lists of
eligible participants admitted to hospital within two
doi: 10.1136/bmj-2021-069761 | BMJ 2022;376:e069761 | the bmj
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weeks of enrollment of case patients with covid-19.
Sites attempted to capture all patients with covid-19
admitted to the hospital during the surveillance
period and targeted a case:control ratio of about 1:1.
Cases and controls were not individually matched.
Respiratory samples from participants were tested
for SARS-CoV-2 both locally in clinical laboratories
and centrally at a research laboratory. Cases were
participants who tested positive for SARS-CoV-2 at
a local laboratory, the central laboratory, or both,
whereas control participants were those who tested
negative for SARS-CoV-2 by all tests. Supplementary
appendix B provides additional details about eligibility
criteria and enrollment practices.13 14

Data collection
Trained staff collected data on demographics, medical
conditions, covid-19 vaccination, and hospital
course through participant (or proxy) interviews and
standardized review of medical records. Details of
covid-19 vaccination, including dates and location of
vaccination, vaccine product, and lot number, were
collected through a systematic process that included
participant (or proxy) interview and source verification
by vaccination card, hospital records, state vaccine
registries, and vaccine records requested from clinics
and pharmacies.13 14
Vaccination status
Vaccine doses were classified as administered if source
documentation of the dose was identified or if the
participant or proxy reported a vaccine dose with a
complete and plausible date and location. This analysis
focused on covid-19 mRNA vaccines authorized or
approved for use in the US, including BNT162b2
(Pfizer-BioNTech) and mRNA-1273 (Moderna).
Participants were classified based on the number of
mRNA vaccine doses received before illness onset: 0
doses (unvaccinated), one dose ≥14 days before illness
(partially vaccinated), two doses ≥14 days before illness
(fully vaccinated), or three doses ≥7 days before illness
(boosted if immunocompetent, or with primary three
dose series completed if immunocompromised). In the
primary analysis, we calculated vaccine effectiveness
for two vaccine doses for participants enrolled
throughout the surveillance period and for three vaccine
doses for participants enrolled after third doses were
authorized in the US.18 19 In a secondary analysis, we
calculated vaccine effectiveness for partial vaccination.
Participants were excluded from this analysis if they
received a covid-19 vaccine other than an mRNA vaccine
(eg, Ad26.COV2 from Janssen/Johnson & Johnson),
more than three vaccine doses, or a third vaccine dose
before they were authorized in the US.18-20
Laboratory analysis
Upper respiratory specimens (nasal swabs or saliva)
were collected from participants, frozen, and shipped
to Vanderbilt University Medical Center, where
they underwent reverse transcription quantitative
polymerase chain reaction (RT-qPCR) for detection of
the bmj | BMJ 2022;376:e069761 | doi: 10.1136/bmj-2021-069761

two SARS-CoV-2 nucleocapsid gene targets (N1 and
N2).21 Respiratory specimens positive for SARS-CoV-2
were shipped to the University of Michigan (Ann Arbor,
MI) for viral whole genome sequencing using the ARTIC
Network protocol on an Oxford Nanopore Technologies
GridION instrument.22 SARS-CoV-2 lineages were
assigned using the Pangolin (phylogenetic assignment
of named global outbreak lineages) nomenclature.23 The
WHO variant assignment was as follows: alpha (B.1.1.7),
beta (B.1.351), gamma (P.1), delta (B.1.617.2 and AY
lineages), and omicron (B.1.1.529 or BA lineages).

Severity of covid-19
We classified the severity of covid-19 based on the
highest severity state reached during the index covid-19
hospital admission using a modified version of the
WHO clinical progression scale (see supplementary
table S2).13 24 In this analysis of patients admitted to
hospital, the scale levels included: admitted to hospital
without supplemental oxygen (level 4), admitted to
hospital with standard supplemental oxygen (level 5),
admitted to hospital with high flow nasal cannula or
non-invasive ventilation (level 6), admitted to hospital
with invasive mechanical ventilation (level 7), admitted
to hospital with mechanical ventilation and additional
organ support (eg, extracorporeal membrane
oxygenation, vasopressors; level 8), and death (level
9). In addition to evaluating the full scale (levels 4-9)
as an ordinal outcome, we also dichotomized the scale
at level 7 to facilitate comparison between patients who
experienced death or invasive mechanical ventilation
(levels 7-9) compared with those who did not experience
death or invasive mechanical ventilation (levels 4-6).
Statistical analysis
We classified cases of covid-19 into alpha, delta,
and omicron variant categories using sequencing
information for cases with lineages identified and
by the predominant circulating variant at the time
of hospital admission for those without a lineage
identified. Periods of predominant circulation for
alpha, delta, and omicron were defined based on
time windows when each variant was identified in
more than 50% of cases successfully sequenced in the
study—alpha period: 11 March to 3 July 2021; delta
period: 4 July to 25 December 2021; and omicron
period: 26 December 2021 to 14 January 2022. For
analyses of vaccine effectiveness to prevent hospital
admissions, we evaluated cases and controls enrolled
during the same period to maintain accuracy of vaccine
effectiveness estimates. For analyses evaluating
vaccine effectiveness against hospital admissions, we
compared cases and controls in each period (alpha,
delta, and omicron); cases were excluded from these
analyses if they had a lineage identified by sequencing
that was discordant with the period (eg, a delta lineage
identified in the omicron period). For severity analyses,
only cases were analyzed, and maintaining a temporal
relationship with a control group was not necessary;
therefore, all cases with sequencing confirmed alpha,
delta, or omicron lineage were analyzed regardless of
3
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admission date; in these analyses, variant group was
classified by sequencing confirmation of alpha, delta,
or omicron lineage, and then by period for other cases.
In sensitivity analyses, we analyzed only cases with
sequencing confirmed variants.
To calculate the effectiveness of mRNA vaccines
(BNT162b2 or mRNA-1273) to prevent hospital
admission with covid-19, we used a test negative
design in which the odds of antecedent vaccination
was compared between cases and controls. We
pooled participants in the test negative and syndrome
negative control groups based on analyses showing
highly similar vaccine coverage in the two control
groups, and nearly identical estimates for vaccine
effectiveness when either control group was used
individually (see supplementary table S3).14 A
multivariable unconditional logistic regression model
was constructed with case-control status as the
dependent variable, vaccination status (vaccinated v
unvaccinated) as the primary independent variable,
and the following covariables selected a priori as
potential confounders: calendar date of admission
in biweekly intervals, US Department of Health and
Human Services region (10 regions), age, sex, and
self-reported race and Hispanic ethnicity. Post hoc,
we considered the following variables for potential
inclusion as covariates, but as none of them changed
the adjusted odds ratio by more than 5% they
were not included in the final analysis: number of
comorbidities, smoking status, living in a long term
care facility before hospital admission, and working
in a healthcare setting. Vaccine effectiveness to
prevent hospital admission with covid-19 [Vaccine
effectiveness(hospital admission)] was calculated with
the adjusted odds ratio from this model as:
Vaccine effectiveness (hospital admission) =
(1−adjusted odds ratio)×100
Using this method, we calculated vaccine
effectiveness against hospital admission with covid-19
separately for the alpha, delta, and omicron variants.
Vaccine effectiveness for two vaccine doses was
calculated for each period, and for three vaccine
doses for the delta and omicron periods. Within each
period we also calculated vaccine effectiveness for
subgroups defined by immunocompromised status,14
age group (18-64 years, ≥65 years), burden of chronic
medical conditions (0; ≥1 medical conditions), and
vaccine product (BNT162b2, mRNA-1273), and for two
vaccine doses recipients, the time between the second
vaccine dose and symptom onset (14-150 days, >150
days). This threshold of 150 days was selected based
on the recommendation for a third (booster) dose of
mRNA vaccine after five months for immunocompetent
adults.23 We report the results for subgroup analyses
that had more than 150 cases and controls.
To show the severity of covid-19 by variant and
vaccination status, we plotted the highest severity level
on the modified WHO clinical progression scale attained
for each case. We then compared severity among
unvaccinated cases by variant (alpha, delta, omicron)
4

and between unvaccinated and vaccinated cases
within each variant group. In these analyses of severity,
patients vaccinated with either two or three doses of an
mRNA vaccine were considered fully vaccinated. These
calculations were performed using a multivariable
proportional odds regression model with WHO clinical
progression scale as the dependent variable (levels 4-9),
variant group (alpha, delta, omicron), or vaccination
status (unvaccinated, vaccinated) as the primary
independent variable, and the following covariables:
age, sex, race and Hispanic ethnicity, and number of
underlying medical conditions (0, 1, 2, 3, or ≥4 classes
of chronic conditions). An adjusted proportional odds
ratio >1.0 from these models indicated more severe
disease for the later variant than a comparator earlier
variant—for example, delta compared with alpha, and
omicron compared with delta.
Next we calculated the vaccine effectiveness of
mRNA vaccines to prevent disease progression to
invasive mechanical ventilation or death among adults
admitted to hospital with covid-19. A multivariable
logistic regression model was constructed with the
composite of invasive mechanical ventilation or
death as the dependent variable, vaccination status
(vaccinated with two or three doses v unvaccinated)
as the primary independent variable, and the same
covariables as included in the severity proportional
odds model. Vaccine effectiveness to prevent inhospital disease progression was calculated as:
Vaccine effectiveness (progression) = (1−adjusted
odds ratio)×100
Using this method, we calculated vaccine
effectiveness against disease progression separately
for the alpha, delta, and omicron groups.
We considered results to be statistically significant
if 95% confidence intervals for odds ratios did not
include the null (odds ratio=1.0), or two sided P
values were <0.05. Missing values were not imputed;
results were presented with denominators to indicate
sample size in each analysis, and models included
participants with complete data for all variables in the
model. Statistical analyses were performed with Stata
version 16 (College Station, TX) and SAS 9.4 (Cary, NC).

Patient and public involvement
Patients and members of the public were not directly
involved in the design of this study. Throughout the
study, patients were routinely engaged in the work
through structured interviews conducted between
research staff and patients in the hospital. These
interviews included questions about patients’
perceptions and understandings of covid-19 vaccines.
Results of the study will be disseminated to the public
through announcements from CDC and through lay and
social media.
Results
Participants and SARS-CoV-2 variants
Between 11 March 2021 and 14 January 2022, 14 128
patients were enrolled across 21 hospitals; 2438
doi: 10.1136/bmj-2021-069761 | BMJ 2022;376:e069761 | the bmj
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Fig 1 | Genome sequenced SARS-CoV-2 variants by week among participants with covid-19 admitted to hospital between 11 March 2021 and 14
January 2022 in 21 hospitals in the United States. Dashed lines represent start of delta variant period (4 July 2021) and start of omicron variant
period (26 December 2021). The figure includes all enrolled cases with a sequencing result, without restriction to cases included in vaccine
effectiveness analyses. SARS-CoV-2 variant lineages were identified for 3017 cases: alpha (n=299), beta (n=8), delta (n=2209), gamma (n=52),
omicron (n=286), and lineage not designated as variant of concern (VOC, n=163)

patients were excluded from the primary analyses,
most commonly for receiving more than one mRNA
vaccine dose but not classifying into the two dose
or three dose vaccine recipient categories (n=933),
or for receiving a non-mRNA vaccine (n=682) (see
supplementary figure S1). The population for analysis
included 11 690 patients, comprising 5728 covid-19
cases and 5962 controls.
Results of SARS-CoV-2 genome sequencing were
obtained for 2599/5728 (45.4%) cases in the analytical
population. Among cases with sequencing completed,
alpha was identified in 242/421 (57.5%) during the
alpha period, delta in 1867/1930 (96.7%) during the
delta period, and omicron in 190/248 (76.6%) during the
omicron period (fig 1; also see supplementary table S4).

Vaccine effectiveness to prevent hospital admission
with covid-19
After excluding 146/5728 (2.5%) cases from the
analysis of vaccine effectiveness against covid-19
related hospital admission who had sequence
confirmed lineage discordant with the variant
predominant period (eg, cases with sequencing
confirmed delta variant during the alpha or omicron
period), we included 5582 cases and 5962 controls in
this part of the analysis. Cases included 1072 from the
alpha period, 3951 from the delta period, and 559 from
the omicron period. Compared with cases in the alpha
and delta periods, cases in the omicron group tended
to be older, have more underlying medical conditions,
and be more likely to have one hospital admission or
more in the past year (table 1, supplementary table
S5). Consistent with increasing vaccine coverage in
the US population over time, a greater proportion
of cases were vaccinated (two or three doses of an
mRNA vaccine) during the omicron period (291/559,
52.1%) than the alpha (119/1072, 11.1%) and delta
(1080/3951, 27.3%) periods.
Vaccine effectiveness for two doses of mRNA vaccine
to prevent hospital admission with covid-19 was
the bmj | BMJ 2022;376:e069761 | doi: 10.1136/bmj-2021-069761

85% (95% confidence interval 82% to 88%) in the
alpha period, 85% (83% to 87%) in the delta period,
and 65% (51% to 75%) in the omicron period (fig 2).
Vaccine effectiveness for three mRNA vaccine doses
in the omicron period was 86% (77% to 91%), which
was similar to the effectiveness of two doses during
the alpha and delta periods. Within the delta period,
vaccine effectiveness for two vaccine doses was lower
when the second vaccine dose was more than 150
days before illness onset (81%, 78% to 84%) than
14-150 days (88%, 86% to 90%). Within the delta
period, vaccine effectiveness of three vaccine doses
(94%, 92% to 95%) was higher than two doses, with
high vaccine effectiveness observed after a third dose
in both immunocompetent (97%, 95% to 98%) and
immunocompromised (87%, 78% to 92%) patients
(fig 2). Within each period, vaccine effectiveness
was lower for immunocompromised compared
with immunocompetent patients and lower for the
BNT162b2 vaccine than for the mRNA-1273 vaccine
(fig 2). Results of sensitivity analyses limited to cases
with sequence confirmed variants were consistent with
those of primary analyses (see supplementary table
S6). Supplementary appendix C presents the vaccine
effectiveness results for partial vaccination (either one
dose of an mRNA vaccine or two doses, with the second
dose received <14 days before illness onset).

Severity of covid-19
The analysis of disease severity included data collected
to 31 January 2022. Of 5728 case patients in the study,
5413 (94.5%) had complete data on clinical outcomes
and were included in the severity analysis, comprising
1060 in the alpha group, 3788 in the delta group, and
565 in the omicron group (table 2). Including both
vaccinated and unvaccinated patients, 582/5413
(11.7%) patients with covid-19 died within 28 days
during the index hospital admission, including 81/1060
(7.6%) in the alpha group, 461/3788 (12.2%) in the
delta group, and 40/565 (7.1%) in the omicron group.
5
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Table 1 | Characteristics of patients admitted to hospital without covid-19 (controls) and with covid-19 (cases) during periods of dominant SARS-CoV-2
variant: alpha (11 March to 3 July 2021), delta (4 July to 25 December 2021), and omicron (26 December 2021 to 14 January 2022). Values are numbers
(percentages) unless stated otherwise
Cases by variant period
Characteristics
Median (IQR) age (years)
Women
Race and ethnicity:
Non-Hispanic white
Non-Hispanic black
Hispanic, any race
Non-Hispanic, other
Unknown
US Census region:
North east
South
Midwest
West
Resident of long term care facility
≥1 hospital admission in past year
Current tobacco use
Median (IQR) No of chronic conditions*
Categories of medical conditions*:
Chronic cardiovascular disease
Chronic pulmonary disease
Diabetes mellitus
Immunocompromising condition*
Obesity
Vaccination status:
Unvaccinated
2 doses (<150 days)
2 doses (≥150 days)
3 doses
Vaccine product received:
BNT162b2 (Pfizer-BioNTech)
mRNA-1273 (Moderna)
Mixed
Median (IQR) days since dose 3

Controls (n=5962)
63 (50-72)
2975 (49.9)

Alpha (n=1072)
56 (43-65.5)
519 (48.4)

Delta (n=3951)
57 (43-69)
1803 (45.6)

Omicron (n=559)
62 (49-73)
264 (47.2)

3611 (60.6)
1240 (20.8)
772 (12.9)
253 (4.2)
86 (1.4)

484 (45.1)
285 (26.6)
220 (20.5)
63 (5.9)
20 (1.9)

2183 (55.3)
820 (20.8)
695 (17.6)
179 (4.5)
74 (1.9)

279 (49.9)
127 (22.7)
111 (19.9)
33 (5.9)
9 (1.6)

885 (14.8)
2371 (39.8)
1374 (23.0)
1332 (22.3)
321/5778 (5.6)
3031/5537 (54.7)
1016/5302 (19.2)
2 (1-3)

158 (14.7)
395 (36.8)
248 (23.1)
271 (25.3)
25/1039 (2.4)
282/956 (29.5)
103/887 (11.6)
1 (1-3)

686 (17.4)
1544 (39.1)
978 (24.8)
743 (18.8)
120/3795 (3.2)
1015/3682 (27.6)
366/3451 (10.6)
1 (0-3)

159 (28.4)
196 (35.1)
104 (18.6)
100 (17.9)
30/534 (5.6)
226/535 (42.2)
59/470 (12.6)
2 (1-3)

4158 (69.7)
1973 (33.1)
1962 (32.9)
1458 (24.5)
2391/5900 (40.5)

589 (54.9)
231 (21.5)
316 (29.5)
172 (16.0)
616/1056 (58.3)

2141 (54.2)
827 (20.9)
1135 (28.7)
659 (16.7)
2099/3909 (53.7)

359 (64.2)
151 (27.0)
164 (29.3)
138 (24.7)
260/556 (46.8)

2054 (34.5)
2029 (34.0)
1411 (23.7)
468 (7.8)
n=3908
2269 (58.1)
1615 (41.3)
24 (0.6)
41 (23-64)

953 (88.9)
119 (11.1)
0 (0)
0 (0)
n=119
81 (68.1)
37 (31.1)
1 (0.8)
—

2871 (72.7)
352 (8.9)
667 (16.9)
61 (1.5)
n=1080
708 (65.6)
368 (34.1)
4 (0.4)
38 (23-65)

268 (47.9)
34 (6.1)
177 (31.7)
80 (14.3)
n=291
203 (69.8)
84 (28.9)
4 (1.4)
69.5 (41.5-97)

IQR=interquartile range.
See supplementary table S5 for baseline characteristics of cases limited to those with a sequencing confirmed variant.
*Obtained using structured medical chart review and defined as one or more of the following: active solid organ cancer (active cancer defined as treatment for the cancer or newly diagnosed
cancer in past six months), active hematologic cancer, HIV infection without AIDS, AIDS, congenital immunodeficiency syndrome, previous splenectomy, previous solid organ transplant,
immunosuppressive drugs, systemic lupus erythematosus, rheumatoid arthritis, psoriasis, scleroderma, or inflammatory bowel disease, including Crohn’s disease and ulcerative colitis.

Among unvaccinated cases, severity of covid-19 on the
WHO clinical progression scale was highest for the delta
group (delta v alpha adjusted proportional odds ratio
1.28, 95% confidence interval 1.11 to 1.46) and lowest
for the omicron group (omicron v alpha 0.79, 0.62 to
1.01; omicron v delta 0.61, 0.49 to 0.77) (fig 3). Among
unvaccinated cases, in-hospital death occurred in 76/944
(8.1%) in the alpha group, 323/2743 (11.8%) in the delta
group, and 25/272 (9.2%) in the omicron group (table
2). Severity of covid-19 on the WHO clinical progression
scale was substantially lower for vaccinated cases than for
unvaccinated cases in each variant group: alpha (adjusted
proportional odds ratio 0.33, 0.23 to 0.49), delta (0.44,
0.37 to 0.51), and omicron (0.61, 0.44 to 0.85).
Across all variants, vaccinated patients with covid-19
who died tended to be older and had multiple medical
conditions or immunocompromising conditions.
Compared with the 424 unvaccinated patients with
covid-19 who died, 158 vaccinated patients who died
were older (median 72 v 61 years; P<0.001), were more
likely to be immunocompromised (41% v 13%; P<0.001),
had more categories of chronic medical conditions
6

(median 3 v 2; P<0.001), and had more prescribed drugs
before hospital admission (median 10 v 5; P<0.001).

Vaccine effectiveness to prevent covid-19
progression after hospital admission
Among patients admitted to hospital with covid-19,
vaccine effectiveness of mRNA vaccination (two or three
doses) to prevent progression to invasive mechanical
ventilation or death was 76% (95% confidence interval
53% to 88%) for the alpha variant, 44% (32% to 54%)
for the delta variant, and 46% (12% to 67%) for the
omicron variant. Vaccine effectiveness to prevent
disease progression was observed in immunocompetent
patients for all three variants but not observed in
immunocompromised patients for the delta or omicron
variant (fig 4). Results were similar when cases were
limited to those with a sequence confirmed variant (see
supplementary table S6).
Discussion
The predominant circulating SARS-CoV-2 variant in
the US changed from alpha to delta in July 2021 and
doi: 10.1136/bmj-2021-069761 | BMJ 2022;376:e069761 | the bmj
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Group*

Covid-19 admissions to hospital
No vaccinated/ No vaccinated/
total cases (%) total controls (%)

VE against covid-19
hospital admission;
% (95% CI)

VE against covid-19
hospital admission;
% (95% CI)

Alpha period (11 March to 3 July 2021) - 2 doses
119/1072 (11.0) 893/1738 (51.4)
Overall
By immunocompromised status†
49/172 (28.5)
218/398 (54.8)
Yes
70/900 (7.8)
675/1340 (50.4)
No
By age group (years)
46/779 (5.9)
18-64
73/293 (24.9)
≥65
By chronic medical conditions‡
4/262 (1.5)
0 chronic conditions
115/810 (14.2)
≥1 chronic condition
By mRNA vaccine product
81/1034 (7.8)
BNT162b2 (Pﬁzer-BioNTech)
37/990 (3.7)
mRNA-1273 (Moderna)

85 (82 to 88)
58 (33 to 73)
90 (87 to 93)

357/985 (36.2)
536/753 (71.2)

87 (82 to 91)

65/208 (31.3)
828/1530 (54.1)

96 (89 to 99)
83 (79 to 87)

519/1364 (38.0)
374/1219 (30.7)

82 (77 to 86)
90 (85 to 93)

Delta period (4 July to 25 December 2021) - 2 doses
1019/3890 (26.2) 2389/3509 (68.1)
Overall
352/3223 (10.9) 1103/2223 (49.6)
2 doses (≤150 days)

85 (83 to 87)
88 (86 to 90)

85 (80 to 89)

667/3538 (18.9) 1286/2406 (53.4)
2 doses (>150 days)
By immunocompromised status†
329/614 (53.6) 570/780 (73.1)
Yes
690/3276 (21.1) 1819/2729 (66.7)
No
By age group (years)
18-64
≥65

81 (78 to 84)
63 (52 to 71)
88 (86 to 90)

427/2586 (16.5) 1152/1957 (58.9)
592/1304 (45.4) 1237/1552 (79.7)

88 (86 to 89)
81 (77 to 84)

By chronic medical conditions‡
63/1057 (6.0)
210/364 (57.7)
0 chronic conditions
956/2833 (33.7) 2179/3145 (69.3)
≥1 chronic condition
By mRNA vaccine product
BNT162b2 (Pﬁzer-BioNTech) 668/3539 (18.9) 1353/2473 (54.7)

96 (95 to 98)
80 (78 to 82)
82 (80 to 84)
88 (86 to 90)

347/3218 (10.8) 1033/2153 (48.0)
mRNA-1273 (Moderna)
Delta period (4 July to 25 December 2021) - 3 doses
61/2932 (2.1) 333/1453 (22.9)
Overall
45/330 (13.6)
165/375 (44.0)
Immunocompromised
16/2602 (0.6) 168/1078 (15.6)
Immunocompetent

94 (92 to 95)
87 (78 to 92)
97 (95 to 98)

Omicron period (26 December to 14 January 2022) - 2 doses
211/479 (44.1) 158/247 (64.0)
Overall
156/382 (40.8) 116/191 (60.7)
Immunocompetent only

65 (51 to 75)
66 (49 to 77)

Omicron period (26 December to 14 January 2022) - 3 doses
80/348 (23.0)
135/224 (60.3)
Overall
39/265 (14.7)
76/151 (50.3)
Immunocompetent only

86 (77 to 91)
86 (75 to 92)
0

50

100

Fig 2 | Vaccine effectiveness (VE) of mRNA vaccines to prevent hospital admissions with covid-19 by variant group, including alpha, delta, and
omicron. *Groups with ≥150 cases and controls were reported. Groups with <150 cases or <150 controls were not reported owing to low precision
of VE estimates with these sample sizes. †Obtained using structured medical chart review, and defined as one or more of the following: active solid
organ cancer (active cancer defined as treatment for the cancer or newly diagnosed cancer in past six months), active hematologic cancer, HIV
infection without AIDS, AIDS, congenital immunodeficiency syndrome, previous splenectomy, previous solid organ transplant, immunosuppressive
drugs, systemic lupus erythematosus, rheumatoid arthritis, psoriasis, scleroderma, or inflammatory bowel disease, including Crohn’s disease
or ulcerative colitis. ‡Obtained using structured medical chart review, and defined as conditions within one or more of the following categories:
cardiovascular disease, neurologic disease, pulmonary disease, gastrointestinal disease, endocrine disease, renal disease, hematologic disease,
malignancy, immunosuppression not captured in other categories, autoimmune condition, or other condition (sarcoidosis, amyloidosis, or
unintentional weight loss ≥10 pounds (4.5 kg) in past 90 days)

then to omicron in December 2021. Understanding
the severity of covid-19 with each variant and the
effectiveness of available vaccines against them is
the bmj | BMJ 2022;376:e069761 | doi: 10.1136/bmj-2021-069761

essential for guiding vaccination policies and directing
future vaccine development. The mRNA covid-19
vaccines that were authorized for use in the US in 2020
7
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Table 2 | In-hospital clinical outcomes among adults admitted with covid-19 by variant group (alpha, delta, omicron). Values are numbers
(percentages) unless stated otherwise

Outcome
Death
Invasive mechanical
ventilation
Composite of death or
invasive mechanical
ventilation
Admitted to intensive
care unit
Non-invasive ventilation
High flow oxygen
Vasopressors
New renal replacement
therapy
Median (IQR) hospital
length of stay among
survivors
Venous thromboembolic
event
Stroke
Myocardial infarction

Alpha group (n=1060)

Delta group (n=3788)

Omicron group (n=565)

Vaccinated
(n=116)
5 (4.3)
7 (6.0)

Unvaccinated
(n=944)
76 (8.1)
201 (21.3)

P value*
0.15
<0.001

Vaccinated
(n=1045)
138 (13.2)
152 (14.5)

Unvaccinated
(n=2743)
323 (11.8)
681 (24.8)

P value*
0.23
<0.001

Vaccinated
(n=293)
15 (5.1)
35 (11.9)

Unvaccinated
(n=272)
25 (9.2)
49 (18.0)

P value*
0.059
0.043

10 (8.6)

218 (23.1)

<0.001

210 (20.1)

748 (27.3)

<0.001

42 (14.3)

54 (19.9)

0.08

24 (20.7)

353 (37.4)

<0.001

321 (30.7)

1179/2742 (43.0)

<0.001

66 (22.5)

89/271 (32.8)

0.006

15 (12.9)
15 (12.9)
6 (5.2)
5 (4.3)

167 (17.7)
324 (34.3)
191 (20.2)
43 (4.6)

0.20
<0.001
<0.001
0.91

151 (14.4)
289 (27.7)
155 (14.8)
49 (4.7)

470 (17.1)
1148 (41.9)
647 (23.6)
159 (5.8)

0.046
<0.001
<0.001
0.18

39 (13.3)
59 (20.1)
36 (12.3)
14 (4.8)

43 (15.8)
84 (30.9)
46 (16.9)
12 (4.4)

0.40
0.003
0.12
0.84

5 (3-8)

5 (3-9)

0.56

5 (3-9)

6 (3-10)

<0.001

5 (3-9)

6 (3-11)

0.050

7 (6.0)

55 (5.8)

0.93

46 (4.4)

250 (9.1)

<0.001

15 (5.1)

22 (8.1)

0.15

0 (0)
1 (0.9)

18 (1.9)
19 (2.0)

0.13
0.39

9 (0.9)
29 (2.8)

44 (1.6)
58 (2.1)

0.08
0.23

3 (1.0)
5 (1.7)

4 (1.5)
5 (1.8)

0.63
0.91

IQR=interquartile range.
*Obtained using χ2 testing, not adjusting for other factors.

(BNT162b2 and mRNA-1273) were highly effective at
preventing hospital admissions for all three variants
during the subsequent year. However, three doses of
an mRNA vaccine were necessary to achieve similar
effectiveness against omicron in the winter of 202122 as two doses achieved for alpha and delta variants
earlier in the year. Furthermore, although hospital
admissions with covid-19 did occur among vaccinated
patients, vaccination was associated with reduced risk
of progression to invasive mechanical ventilation or
death for all three variants.
Among unvaccinated adults admitted to hospital
with covid-19, the delta variant was associated with
the most severe disease, followed by the alpha variant
and then the omicron variant. Among unvaccinated
patients admitted to hospital, covid-19 due to the
omicron variant was about 79% and 61% as severe
as covid-19 due to the alpha and delta variants,
respectively. The omicron variant was, however,
associated with substantial critical illness and death,
with 15% of patients admitted to hospital with the
omicron variant (vaccinated and unvaccinated)
progressing to invasive mechanical ventilation, and
7% dying in hospital.

Strengths and limitations of this study
This work has several strengths. The vaccine
effectiveness analyses applied a test negative design
to a large population of patients admitted to hospital
with symptomatic, laboratory confirmed covid-19
along with concurrent controls, which enabled control
for healthcare seeking behavior, robust subgroup
analyses, and evaluation of outcomes beyond hospital
admission, including level of respiratory support and
mortality. Ascertainment of vaccination status was
robust, with trained staff conducting patient interviews
8

and searching multiple sources of vaccination records
on a patient-by-patient basis. Respiratory samples
collected in the study underwent centralized RT-qPCR
testing and viral whole genome sequencing, which
enabled precise characterization of time periods
dominated by different variants.
The study also has limitations. First, use of in-patient
controls might lead to biased estimates if control
patients had different characteristics from people in
the general community; however, vaccine coverage in
the control population within this study tracked closely
with that in the adult population in the US.25 Second,
this study only evaluated patients admitted to hospital
and thus does not inform vaccine effectiveness against
mild covid-19 or differences in disease severity among
people with SARS-CoV-2 variants in the outpatient
setting. Third, the study only evaluated mRNA
vaccines, not other types of covid-19 vaccines. Fourth,
the analyses of in-hospital severity did not account for
potential differences in clinical management during the
periods when the alpha, delta, and omicron variants
predominated that may have impacted outcomes. Fifth,
although the test negative design is the preferred method
for evaluating vaccine effectiveness with observational
data,16 it has known potential limitations, including
collider bias 26 27; the risk of collider bias was minimized
in the current study by evaluating only severely ill
patients.16 Sixth, sequencing did not identify a variant
for some cases—typically those with low viral loads
in tested respiratory samples. Variant classification
for cases without a sequencing confirmed variant was
based on the predominant circulating variant at the
time; variant misclassification was possible for these
cases, but sensitivity analyses limited to sequencing
confirmed cases produced results similar to those in the
primary analysis.
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Percentage

Death
Invasive mechanical ventilation plus other organ support
Invasive mechanical ventilation
Non-invasive ventilation or high ﬂow nasal cannula
Low ﬂow oxygen
No supplemental oxygen
100

Unvaccinated cases

80
60
40

record data from sites across the US, the VISION Network
recently estimated mRNA vaccine effectiveness against
hospital admissions due to the omicron variant to be
to 52% for two vaccine doses, with the second dose
received within 180 days before illness onset, 38% for
two doses received more than 180 days before illness
onset, and 82% for three vaccine doses.11 Previous
studies largely relied on estimating the predominant
circulating SARS-CoV-2 variants from external data.
This study adds vaccine effectiveness results against
severe disease using sequencing data from within the
study and found strong protection against the omicron
variant with three mRNA vaccine doses in the first
several months after receipt of a third dose.

20

Percentage

0
100

(n=944)

(n=2743)

(n=272)

(n=1045)
Delta

(n=293)
Omicron

Vaccinated cases

80
60
40
20
0

(n=116)
Alpha

Fig 3 | Severity of covid-19 during index hospital admission among adults with
covid-19, by SARS-CoV-2 variant for unvaccinated and vaccinated patients. Disease
severity was classified based on the highest severity level reached on the World Health
Organization clinical progression scale, which ranged from hospital admission without
supplemental oxygen (lowest level) to death (highest level). Among unvaccinated
patients, severity was higher for the delta than alpha variant (adjusted proportional
odds ratio 1.28, 95% confidence interval 1.11 to 1.46) and lower for the omicron than
delta variant (0.61, 0.49 to 0.77). For each variant, severity was lower for vaccinated
patients (two or three doses of an mRNA vaccine) than unvaccinated patients, including
for alpha (adjusted proportional odds ratio 0.33, 0.23 to 0.49), delta (0.44, 0.37 to
0.51), and omicron (0.61, 0.44 to 0.85)

Comparison with other studies
Earlier studies from England5 and Scotland4 found
an increased risk of hospital admission with the delta
variant compared with alpha variant. More recent
studies have suggested that people with a diagnosis of
covid-19 due to the omicron variant are less likely to be
admitted to hospital than those with the delta variant.8
This study adds robust measurements of disease
severity after hospital admission and shows that the
delta variant was associated with more severe covid-19
than the alpha and omicron variants, driven largely by
higher rates of advanced respiratory support.
Emerging vaccine effectiveness estimates globally
suggest reduced effectiveness against the omicron
variant compared with previous variants,28-30
including an estimate of 70% vaccine effectiveness for
two doses of the BNT162b2 vaccine to prevent hospital
admissions due to the omicron variant in South Africa
in November-December 2021.9 Using electronic health
the bmj | BMJ 2022;376:e069761 | doi: 10.1136/bmj-2021-069761

Policy implications
These data indicate that the omicron variant is
associated with serious covid-19 among those
admitted to hospital, and preventive measures are
needed. Vaccination with existing mRNA vaccine
formulations is an effective preventive measure against
the omicron variant, both for the prevention of hospital
admissions and for the prevention of progression to
critical illness and death among those admitted to
hospital. Third doses of mRNA vaccines are needed
to achieve high levels of protection. These findings
support recent recommendations in the US for a third
mRNA vaccine dose for both immunocompetent19 and
immunocompromised18 adults as a key approach to
protecting populations against the omicron variant.
The serial emergence of new SARS-CoV-2 variants,
including delta and omicron, has challenged public
health agencies to develop vaccine policies that
counter the impact of waning immunity (the decline in
protection of vaccine doses over time against the same
variant) and viral immune evasion (new viral variants
that are less susceptible to existing vaccines). Vaccine
booster doses of the same vaccine formulation used
in the primary vaccine series are designed to counter
waning immunity. Substantial viral immune evasion
would require new vaccine formulations targeting
new variants to maintain protection. Boosters were
implemented in several countries in response to
covid-19 spikes with emergence of the delta variant.
This study suggests that these booster doses were
largely effective in preventing severe disease with both
the delta variant and subsequently with the omicron
variant. As the covid-19 pandemic continues to evolve,
routine monitoring of vaccine effectiveness, especially
against severe disease, and surveillance programmes
to identify viral variants will be essential to inform
decisions about booster vaccine policies and vaccine
strain updates.
Conclusions
In this large, multistate study of adults in the US,
mRNA vaccines were associated with strong protection
against hospital admissions with covid-19 due to the
alpha, delta, and omicron variants. Furthermore, for
each of the variants, vaccination was associated with a
reduced risk of covid-19 progressing to critical illness
9
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Subgroup

No with IMV or death/ No with IMV or death/
total vaccinated (%) total unvaccinated (%)

Alpha variant
Overall
10/116 (8.6)
By immunocompromised status
Yes
3/47 (6.4)
No
7/69 (10.1)
By age group (years)
18-64
4/44 (9.1)
≥65
6/72 (8.3)
Delt variant
Overall
210/1045 (20.1)
By immunocompromised status
Yes
85/360 (23.6)
No
125/685 (18.2)
By age group (years)
18-64
76/438 (17.4)
≥65
134/607 (22.1)
Omicron variant
Overall
42/293 (14.3)
By immunocompromised status
Yes
13/95 (13.7)
No
29/198 (14.6)
By age group (years)
18-64
18/141 (12.8)
≥65
24/152 (15.8)

VE against disease
progression aer
covid-19 hospital
admission; % (95% CI)

VE against disease
progression aer
covid-19 hospital
admission; % (95% CI)

218/944 (23.1)

76 (53 to 88)

24/124 (19.4)
194/820 (23.7)

77 (7 to 94)
73 (39 to 88)

153/723 (21.2)
65/221 (29.4)

68 (5 to 89)
77 (42 to 91)

748/2743 (27.3)

44 (32 to 54)

64/263 (24.3)
684/2480 (27.6)

15 (-26 to 43)
50 (37 to 60)

541/2069 (26.1)
207/674 (30.7)

49 (32 to 62)
44 (26 to 57)

54/272 (19.9)

46 (12 to 67)

9/44 (20.5)
45/228 (19.7)

42 (-61 to 79)
44 (0 to 69)

35/185 (18.9)
19/87 (21.8)

55 (7 to 78)
37 (-32 to 69)
-50

0

50

100

Fig 4 | Effectiveness of two or three doses of mRNA vaccines among adults admitted to hospital with covid-19 to prevent disease progression to
invasive mechanical ventilation (IMV) or death, by SARS-CoV-2 variant. VE=vaccine effectiveness

or death. Although disease severity for in-hospital
patients was somewhat lower for the omicron variant
than alpha and delta variants, patients admitted to
hospital with covid-19 due to the omicron variant
still had a substantial risk of critical illness and
death. These findings suggest that vaccination against
covid-19, including a third dose of an mRNA vaccine,
is critical for protecting populations against covid-19associated morbidity and mortality.
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